MNKD - NASDAQ
MannKind Corporation
$3.36
-2.0%MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.
At a Glance
Live Snapshotmnkd
Operating Expenses
Last Annual Value
249.00M
3-Year CAGR
33%
5-Year CAGR
23%
10-Year CAGR
2%
MannKind Corporation Competitors Analysis of Operating Expenses
| Company | Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
MannKind Corporation NASDAQ:MNKD | 249.00M | 25.0% | 24.4% | 15.4% | |
 Janux Therapeutics, Inc. NASDAQ:JANX | 165.64M | 27.9% | 35.3% | N/A | |
 Biohaven Ltd. NYSE:BHVN | 741.24M | 19.3% | 27.6% | N/A | |
 Celldex Therapeutics, Inc. NASDAQ:CLDX | 288.90M | 88.1% | 66.5% | 7.5% | |
 Harmony Biosciences Holdings, Inc. NASDAQ:HRMY | 461.64M | 19.8% | 23.2% | N/A | |
 Sionna Therapeutics, Inc. NASDAQ:SION | 88.33M | 20.6% | N/A | N/A | |
 Vera Therapeutics, Inc. NASDAQ:VERA | 315.47M | 45.7% | 55.8% | N/A | |
 Nuvation Bio Inc. NYSE:NUVB | 267.52M | 38.9% | 23.4% | N/A |
MannKind Corporation Fair Value Envelope
Related Guides
Continue your MNKD research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.